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D
ifferentiated thyroid cancer (DTC) is the most common endocrine malignancy (1, 2) . Its incidence rates have been increasing during the past 4 decades (1) (2) (3) (4) . Although the exact reasons for this increasing incidence are not fully understood, advances in diagnostic methods and the widespread use of neck ultrasonography have substantially contributed to the discovery of many tumors that would have otherwise remained undiagnosed (1, 3, 4) . The mortality from thyroid cancer (TC) remains low, although recent data have suggested that it has also been increasing owing to the greater incidence of more advanced stages of TC (4) .
Most cases of TC occur in women in their third and fourth decades of life (5) . Although a similar trend of an increasing incidence of TC has been observed in children (6) (7) (8) , DTC remains rare in children.
Pediatric TC has been defined as TC occurring in children and adolescents aged #18 years (9) . DTC in children seems to be distinct from that in adults (6, 10) . It is characterized by aggressive histopathological features with high rates of lymph node (LN) and distant metastases (6, 10) . However, the long-term outcomes have usually been favorable (11) . Owing to the substantial differences in the clinical presentation and outcomes between pediatric and adult TC, the American Thyroid Association published clinical practice guidelines specifically focusing on the management of pediatric TC (9) . However, owing to its rare occurrence, the data for pediatric DTC are deficient, and many of the recommendations of these guidelines were extrapolated from data for adult DTC (9) . Therefore, more data on pediatric TC are needed to guide evidence-based clinical practice and management.
One of the major differences between pediatric and adult DTC is the high frequency of lung metastasis in the former compared with the latter (6, 12) . Lung metastases have been reported to occur in 7% to 30% in this age group (6) compared with only~4% in the adult population (6, 12) . Only a few older studies have reported in general terms on lung metastases in pediatric TC or included patients in the pediatric age (13) (14) (15) . Therefore, additional studies are needed in which patients were treated according to the current standard of care for DTC in children. In the present study, we report a series of pediatric DTC cases with lung metastasis and describe their histopathological features, radiological patterns of lung metastases, mutational data, response to radioactive I-131 therapy, and long-term outcomes.
Patients and Methods
After obtaining institutional review board approval of the King Faisal Specialist Hospital and Research Centre (Riyadh, Saudi Arabia), we studied all patients with pediatric TC seen at our hospital from January 2002 to July 2018. Using the Cancer Registry of the King Faisal Specialist Hospital and Research Centre, 110 patients (median age, 15.6 years; range 8 to 18 years) with pediatric TC diagnosed at age #18 years were treated during the study period. Of these 110 patients, 21 (19%) had lung metastases at diagnosis. We retrospectively reviewed their medical records and extracted the clinical, pathological, and radiological data pertinent to our study. They had presented with thyroid nodules with or without cervical lymphadenopathy detected on physical examination and/or neck ultrasonography. All 110 patients had undergone total thyroidectomy and therapeutic central LN dissection. In addition to central LN dissection, 3 patients (15%) had undergone ipsilateral neck dissection and 16 (80%) had undergone bilateral LN dissection. The patients were seen 6 to 8 weeks after surgery and after not receiving levothyroxine for $4 weeks and liothyronine sodium (Cytomel; Pfizer, New York, NY) for $2 weeks. At that time, a diagnostic radioactive iodine (I-123) whole body scan (DxWBS) and neck ultrasonography were performed, and serum thyroglobulin (Tg), anti-Tg antibodies, TSH and free T4 (FT4) were measured. I-131 was administered at activities that averaged 150 to 200 mCi for a 70-kg patient, adjusted for body weight. The selection of I-131 therapeutic activities was empirical but was determined from the generally recommended therapeutic activities of 150 to 200 mCi for lung metastasis in 70-kg adults adjusted to the body weight of the child with consideration of the extent of lung involvement found on the DxWBS. The initial I-131 therapies were administered every 6 to 12 months, as also recommended to eradicate the lung metastases. For patients who required more than two doses, after the initial therapy, subsequent therapy was sometimes delayed for an additional year to minimize I-131 toxicity. The patients were treated with additional I-131 therapy when persistent evidence of disease was found on DxWBS and Tg was detectable. I-131 therapy was stopped when the metastases were no longer I-131 avid, the administrative doses were .1000 mCi, or when evidence was found of progression despite repeated therapy with I-131. Thyroid hormone suppressive doses were prescribed to suppress TSH to ,0.01 mU/L with FT4 level at the upper or just slightly greater than the upper limit of normal. Monitoring of these patients was achieved by periodic (usually every 3 to 9 months) measurement of TSH, FT4, Tg, and anti-Tg antibodies, neck ultrasonography, DxWBS, and CT scan of the lungs. CT scan of the lungs was performed in patients with lung uptake found on the DxWBS or post-therapy whole body scan. It was also performed in patients in whom the serum Tg level was substantially high (stimulated Tg, .100 ng/dL) in the absence of important findings on neck ultrasonography that could explain the elevation in serum Tg.
Molecular testing for the purpose of the present study was performed retrospectively. The pathological tissue from the primary TC of each patient was examined by an experienced endocrine pathologist (H.A.), and tumor tissue was carefully dissected from formalin-fixed paraffin-embedded tissues. DNA was extracted using a commercial DNA extraction kit [QIAamp DNA FFPE (formalin-fixed paraffin-embedded) Tissue Kit; catalog no. 56404; Qiagen, Hilden, Germany) according to the manufacturer's instructions. DNA was quantified using a nanodrop2000 spectrophotometer (Thermo Scientific, Wilmington, Delaware, USA), and DNA purity was ensured by the A260/280 ratio of $1.8 indicating good purity DNA. We used PCR and direct sequencing using Big Dye terminator, version 3.1, cycle sequencing reaction kit and an ABI PRISM 3730XL genetic analyzer (Applied Biosystems). The genes tested included BRAF exon 15, TERT promotor C228T and C250T mutations, HRAS exons 2 and 5, KRAS exons 2 and 5, NRAS exons 2 and 5, PIK3CA exons 9 and 20, PTEN exons 5, 6, 7, and 8, EIF1AX exons 1 and 2, CHEK2 exons 10 and 14, and PPM1D exons 2, 5, and 6 using the same primers and PCR conditions as previously described (16) . Although fusion genes, including RET/PTC1 and RET/PTC3, are fairly frequent in pediatric TC, they were not tested for in the present study for technical reasons. Testing for these fusion genes entails isolation of RNA from formalin-fixed paraffin-embedded tissue, which was repeatedly unsuccessful owing to degradation of RNA.
Results

Demographic and histopathological features
Of the 110 patients with pediatric DTC, 21 (19%) had lung metastases. One patient was lost to follow-up after he had undergone total thyroidectomy and had received the first dose of I-131 and excluded from further analysis. The other 20 patients included 4 males and 16 females (male/female ratio~1:4), with a median age of 14.5 years (range, 10 to 18 years). The main demographic and histopathological features of these patients with lung metastases and those without evidence of distant metastases are summarized in Table 1 . None of the patients had a history of head and neck irradiation. None of the patients had a family history of known hereditary syndromes associated with an increased risk of DTC (e.g., Cowden syndrome). However, one patient had a family history of TC in her mother (patient 5; Table 2 ). The median tumor size was 5 cm (range, 2 to 8 cm). The rates of tumor multifocality (65%), bilaterality (65%), extrathyroidal extension (75%), lymphovascular invasion (60%), and LN metastases (95%) were high, consistent with the invasive nature of these metastatic tumors.
Lung metastasis pattern
TC lung metastases have been previously categorized in three patterns: (i) metastases found only on the DxWBS and not on the lung CT scan; (ii) micrometastases found on the DxWBS and CT scan of the chest but with a size of #1 cm; and (iii) macrometastases found on the DxWBS and CT scan of the chest with the size of one or more .1 cm (17) . In the present study, 3 patients (15%) had lung metastases found only on the DxWBS, 16 patients (80%) had micrometastases, and 1 patient (5%) had macrometastases (Tables 2 and 3 ). The pattern in all cases was widespread bilateral lung nodules. No patient had skeletal or other sites of metastasis.
Molecular testing of primary tumors
We screened for known single point mutations in 10 of the 20 patients studied. The remaining patients were not studied because tissue from the original tumors was not available. No mutation was found in any of the genes cited in the Methods section in the 10 patients studied, except that one tumor carried two mutations in the PIK3CA gene (Q530R and A533V). As a control, we concurrently tested tumor samples with known positive and negative mutations, and the results of those tests were consistent with the known mutation status.
Therapy for and outcome of lung metastasis
All patients were treated with at least one dose of I-131 therapy ( Table 2 ). The first I-131 therapy was given within 6 to 8 weeks after surgery during TSH stimulation using withdrawal of thyroid hormones. The median initial I-131-administered activity was 150 mCi (range, 54 to 211 mCi). Additional I-131 therapies were given to 15 patients (75%). The total number of I-131 therapies received ranged from one to eight times (median, three). Five patients received only one therapy, four patients received two, six patients received three, two patients received four, two patients received five, and one patient received eight therapies ( Table 2 ). The median cumulative administered I-131 activity was 317.5 mCi (range, 109 to 682 mCi). Additional therapeutic interventions included repeat neck surgery for neck recurrence and/or persistent disease in six patients (30%), external beam radiotherapy to the neck in one patient, and sorafenib for one patient.
Biochemical response
At the first I-131 therapy, the anti-Tg antibodies were significantly elevated in seven patients (35%), ranging from 572 to .4000 U/L (normal range for the assay used, 0 to 115 U/L). Thus, the Tg levels were unreliable in these patients. Only in one patient had the anti-Tg antibodies decreased substantially from 1348 U/L at the first I-131 therapy to 17 U/L at the last follow-up visit. In the other six patients, the anti-Tg antibodies had either remained at Data presented as median and range, n (%), or n.
Abbreviation: PTC, pediatric TC.
doi: 10.1210/jc.2018-01690 https://academic.oup.com/jcemthe same level or even increased further, probably reflecting persistence or worsening of lung metastases. In one patient who had been treated initially at another hospital, the Tg level at the first I-131 therapy was not available. Of the remaining 12 patents (60%) with longterm follow-up data available, the Tg level had significantly declined in all 12 (Fig. 1 ). The median stimulated Tg level at the first I-131 therapy was 889.5 U/L (range, 4.1 to 8825 U/L) and at the last visit was 10.5 U/L (range, 0 to 1226 U/L).
Structural response
Three patients (15%) were initially discovered to have lung metastases on the DxWBS only (Tables 2 and 3) . Their initial CT scans of the lungs revealed no lung nodules. None of these three patients (15%) developed lung nodules during long-term follow-up (Table 2) . However, their stimulated Tg levels continued to be detectable, and one patient had persistent radioiodine uptake in the lungs found on the follow-up DxWBS. In the 16 patients with micrometastases, only 1 had shown complete resolution of the micrometastases at the last follow-up CT scan of the lung (Tables 2 and 3 ). However, he continued to have detectable Tg levels (1.8 mg/dL) but with very high anti-Tg antibodies (.4000 U/L). Fifteen patients (75%) continued to have evidence of several bilateral lung nodules of ,1 cm, consistent with micrometastases from TC. All 15 patients had had a substantial decrease in their serum Tg, although 7 also had anti-Tg antibodies. Thus, the importance of the Tg decrease was questionable. One of these 16 patients developed progression of lung metastases; the other 15 patients had stable lung nodules. In one patient (5%), the lung metastases were macrometastases (.1 cm) that progressively increased in size and led to the death of that patient (Tables 2 and 3) . Response determined using definitions from the 2015 American Thyroid Association Guidelines. Data presented as n (%). a Persistent uptake on the DxWBS, although the findings from the CT scan of the chest were negative.
Overall response according to American Thyroid Association response status
The overall response was evaluated using the American Thyroid Association guidelines (18) . The median follow-up period was 8.2 years (range, 0.75 to 16.3 years). None of the patients achieved an excellent response (Table 3) . Two patients (10%) achieved an indeterminate response with negative findings on imaging studies and a stimulated Tg level of 2.4 and 1.8 mg/dL, respectively. The latter patient also had elevated anti-Tg antibodies, making his status indeterminate regardless of the Tg level. One patient (5%) had a biochemically incomplete status. Fifteen patients (75%) continued to have evidence of structurally stable disease in the form of bilateral lung nodules ,1 cm in size, one patient (5%) had progressive structural disease in the form of growing micrometastases and one patient (5%) died of progressive lung macrometastases (Tables 2 and 3 ). The last patient who died of progressive lung metastasis was a 15-year-old girl who had presented with locally invasive poorly DTC, insular type. She had underwent total thyroidectomy and bilateral neck dissection, followed by 150 mCi I-131. The patient had had bilateral lung metastases on the DxWBS and CT scan of the chest. Three months after I-131 therapy, she presented with several large (3 to 4 cm) cervical LN metastases and rapidly increasing lung metastases found on the CT scan of the chest. She was treated with sorafenib, because she was deemed to have inoperable, progressive, radioiodine refractory and metastatic poorly DTC. Her disease progressed, and she died 1.5 months after starting sorafenib.
Discussion
In the present study, we analyzed the characteristics of lung metastases in patients with pediatric TC. Our analysis showed that lung metastases are common (19%) in this age group and are usually in the form of bilateral diffuse micrometastases (80%). They frequently respond to I-131. However, treatment with this modality was rarely curative, although benefit from I-131 is likely given the stability of the disease and the biochemical and radiological response in most cases. However, progression and mortality from lung metastases in pediatric patients with DTC are rare in the first decade after diagnosis (Tables 2 and 3 ). Whether this excellent outcome resulted from I-131 therapy or the indolent natural course of lung metastases in pediatric DTC is unclear.
Several studies have shown that DTC in children, compared with adult DTC, commonly presents with larger tumors and with high rates of extrathyroidal extension, tumor multifocality, bilaterality, and LN and distant metastases (6, 12, (19) (20) (21) (22) (23) (24) (25) . Although lung metastases are relatively rare in adults, they are common in pediatric DTC, ranging from 7% to 30% (6, 12, 22, 24, 25) . We previously compared pediatric DTC (patient age, #18 years) with DTC in a group of young adults (age, 18 to 45 years) (12) . Pediatric DTC was more invasive, with greater rates of regional and distant metastases and less chance of remission compared with DTC in the young adults (12) . We hypothesized that this could result from differences in the underlying molecular pathogenesis between DTC in these two age groups. Further work from our group and others has shown substantial differences in the rates of known somatic mutations commonly detected in adult DTC (6, 16, (26) (27) (28) . The BRAF V600E mutation was~50% less frequent and HRAS, NRAS, KRAS, PTEN, PIK3CA, and TERT promoter mutations were extremely rare in pediatric compared with adult DTC (6, 16) .
In the present study, we also found no mutations except a double mutation (Q530R and A533V) in 1 of 10 cases of pediatric DTC with lung metastases that were tested for mutations. Although the number of tumors tested was small (10 of 20 patients), we were surprised to find a very low rate of the common mutations in these patients. One particular observation was the absence of BRAF V600E and TERT promoter mutations, which have been associated with more aggressive tumors (29) (30) (31) (32) . However, previous studies, including some studies from our group, have reported much lower rates of these mutations in pediatric DTC compared with adult DTC (6, 16, 24, 26) . In one study, the BRAF V600E mutation was found in only 24% of pediatric DTC cases and NRAS, KRAS, HRAS, PIK3CA, PTEN, and TERT promotor mutations were extremely rare in pediatric DTC cases (16) . It has been known that fusion genetic alterations are most common in pediatric DTC (6, 27, 33) . However, these were not tested in the present study for technical reasons. It is possible that these fusion genes are common in patients with lung metastases, although previous studies have not shown a consistent prognostic value for fusion proteins, except in radiation-induced pediatric TC, in which RET/PTC1 and RET/PTC3 were associated with more aggressive DTC (33) (34) (35) (36) (37) . In addition, other genetic alterations, in either the primary tumors or the metastatic lesions, might be the driving mechanisms for pediatric DTC and its metastasis. Unlike adult DTC (38) , a comprehensive molecular landscape using next generation sequencing platforms and other advanced technologies has, to the best of our knowledge, not yet been reported for pediatric DTC.
Lung metastases in adult DTC are rare but represent a major change in the prognosis, especially for older patients. The American Joint Committee on Cancer classification, version 8, used an age limit of 55 years as a cutoff limit for staging DTC (39) . Patients younger than that age are classified as having stage II if they have lung metastases and those aged $55 years as having stage IVB DTC if they have lung metastases (39) . In a study of 444 patients with lung metastases and with or without bone metastases treated at a single center in Europe for 41 years (study period, 1953 to 1994), the overall survival rates were 42% at 10 years, 33% at 15 years, and 29% at 20 years (17) . Patients with uptake found on the DxWBS had significantly better survival rates at 10, 15, and 20 years compared with those without uptake. Patient age and the type of metastasis were important prognostic factors, with the worst prognosis for those aged .40 years and with macrometastasis ($1 cm) and the best prognosis for those aged ,40 years and with metastases found only on the DxWBS (17) . That study included 37 pediatric patients (age, 4 to 19 years). Of these 37 patients, 7 died of distant metastases, and the 10-, 15-, and 20-year survival rates in this age group were 100%, 90%, and 87%, respectively (17) . In our study, 3 patients (15%) presented with metastases seen only on the DxWBS with no evidence of metastasis found on the CT scans of the lung (Table 2) . Although these patients could be expected to achieve the best response, none of them achieved an excellent response. Excluding one patient with poorly DTC who had presented with macrometastases, all other patients presented with uptake on the DxWBS, and 80% had micrometastases found on the CT scan of the lungs. Repeated therapies with I-131 (median number, three) resulted in a substantial biochemical response in the serum Tg level (Fig. 1) and disappearance of uptake on the DxWBS in all but one patient (Table 2) . However, only one patient showed complete resolution of the CT scan abnormalities (lung nodules), although he continued to have mildly elevated Tg levels (indeterminate response). The biochemical response and the disappearance of uptake on the DxWBS suggest the effectiveness of I-131 therapy (Table 2 ; Fig. 1 ). It is possible that the persistent lung nodules were scar tissue or minimal residual lung metastases. In such cases, observation and periodic monitoring might be an appropriate approach because scar tissue is unlikely to change and any residual lung metastases could increase in size or number.
Our study had a number of shortcomings, including the relatively small sample size. However, pediatric TC is rare, and 20 patients with lung metastases from pediatric TC is an informative sample. Another limitation of our study was that the molecular testing was performed in only 50% of cases and we used Sanger sequencing methods rather than the more modern and sensitive next generation sequencing. We also did not test for the known fusion genes that are more common in pediatric TC. However, the present study is the first to our knowledge that has attempted to assess the underlying molecular alterations in pediatric TC with lung metastases, and Sanger sequencing has been the method used in most previous molecular research of DTC.
In conclusion, lung metastases are relatively common in patients with pediatric TC. They present most frequently with widespread radioiodine-avid nodules of #1 cm (micrometastases). Common single point mutations seen in adult DTC, including mutations associated with more aggressive disease, such as BRAF V600E and TERT promotor mutations, are rare in pediatric DTC. The biochemical response to I-131 will usually be good. However, complete resolution of lung metastases or achieving undetectable Tg levels seems rare. In addition, mortality from lung metastases in pediatric TC is extremely rare, and long-term survival with stable structural disease is common.
